Last update April 16, 2024
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
N-{N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-l-alanyl}-l-proline hydrogen maleate is Enalapril in Chemical name.
Is written in other languages:N-{N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-l-alanyl}-l-proline hydrogen maleate is also known as
N-{N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-l-alanyl}-l-proline hydrogen maleate belongs to these groups or families:
Main tradenames from several countries containing N-{N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-l-alanyl}-l-proline hydrogen maleate in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Enalapril is an angiotensin converting enzyme inhibitor (ACE inhibitor) used in the treatment of arterial hypertension and heart failure. Oral administration every 12-24 hours.
It is excreted in breast milk in a clinically insignificant amount (Anderson 2018, Serrano 2015, Rush 1991, Redman 1990, Kirsten 1998, Huttunen 1989) and no problems have been observed in infants whose mothers took it (Anderson 2018, Rush 1991, Huttunen 1989), nor problems in establishing breastfeeding. (Bach 1995).
It is a licensed medication for use in young infants and, off-label, in neonates.(FDA 2018, Kirsten 1998).
Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity.(Serrano 2015)
Expert authors and medical associations such as the American Academy of Pediatrics consider it a medication usually compatible with breastfeeding (Hale, LactMed, Ghelfi 2021, Serrano 2015, Rowe 2013, Dennis 2012, Ghanem 2008, AAP 2001, Kirsten 1998).
The protective role of breastfeeding against maternal hypertension has been proven.(Park 2018).